CVRx's stock up as heart failure device to be trialled in expanded patient group [Yahoo! Finance]
CVRx, Inc. (CVRX)
Company Research
Source: Yahoo! Finance
In the BENEFIT-HF clinical trial (NCT07232030), Barostim will be trialled in patients with heart failure who remain symptomatic after receiving optimised guideline-directed medical and device therapies (GDMT), have a left ventricular ejection fraction (LVEF) If successful, the BENEFIT-HF trial could expand the indicated patient population for Barostim approximately three times, significantly broadening access to this neuromodulation-based approach to heart failure management. Barostim is an implantable neuromodulation device that delivers electrical signals to baroreceptors located on the carotid artery, increasing baroreflex signalling, rebalancing the autonomic nervous system, and improving heart failure symptoms. It gained US Food and Drug Administration (FDA) approval in 2019 following its designation under the FDA's Breakthrough Devices Program and is now commercially available in both the US and Europe. The device is already approved for use in heart failure patients who
Show less
Read more
Impact Snapshot
Event Time:
CVRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVRX alerts
High impacting CVRx, Inc. news events
Weekly update
A roundup of the hottest topics
CVRX
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRXGlobeNewswire
- CVRx ALERT: Bragar Eagel & Squire, P.C. is Investigating CVRx Inc. on Behalf of CVRx Stockholders and Encourages Investors to Contact the FirmGlobeNewswire
- CVRx INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities FraudBusiness Wire
- CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026GlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRXPR Newswire
CVRX
Earnings
- 11/5/25 - Beat
CVRX
Sec Filings
- 1/12/26 - Form SCHEDULE
- 1/12/26 - Form 8-K
- 1/12/26 - Form 424B5
- CVRX's page on the SEC website